In vitro reoxygenation following hypoxia increases MMP-2 and TIMP-2 secretion by human umbilical vein endothelial cells

• Autorzy: Cavdar Z. , Oktay G. , Egrilmez M.Y. , Genc S. , Genc K. , Altun Z. , Islekel H. , Guner G.
• Języki publikacji: EN

Abstrakty

EN

 Endothelial cells lining the inner blood vessel walls play a key role in the response to hypoxia, which is frequently encountered in clinical conditions such as myocardial infarction, renal ischemia and cerebral ischemia. In the present study we investigated the effects of hypoxia and hypoxia/reoxygenation on gelatinases (matrix metalloproteinase-2 and -9), their inhibitor (TIMP-2) and activator (MT1-MMP), in human umbilical vein endothelial (HUVE) cells. HUVE cells were subjected to 4 h of hypoxia or hypoxia followed by 4 and 24 h of reoxygenation. The pro- and active forms of MMP-2 and MMP-9 were analyzed by gelatin zymography; TIMP-2 protein level was assayed using ELISA, while MT1-MMP activity was measured using an activity assay. The secretion of MMP-2 proform increased significantly in cells subjected to 4h of hypoxia followed by 4 or 24 h of reoxygenation, compared with the normoxic group. TIMP-2 protein level also increased significantly in the hypoxia/reoxygenation groups, compared with the normoxic group. There were no statistically significant differences in the levels of active MT1-MMP in all groups. This study indicates that MMP-2 and TIMP-2 could be regarded as important components of a mechanism in the pathophysiology of ischemic injury following reperfusion.

Słowa kluczowe

EN

hypoxia; matrix metalloproteinase 2; tissue inhibitor; endothelial cell; reoxygenation; umbilical vein; human umbilical vein

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2010
• Tom: 57
• Numer: 1
• Opis fizyczny: p.69-73,fig.,ref.

Twórcy

autor

Cavdar Z.

• Dokuz Eylul University, Inciralti, Izmir, Turkey

autor

Oktay G.

autor

Egrilmez M.Y.

autor

Genc S.

autor

Genc K.

autor

Altun Z.

autor

Islekel H.

autor

Guner G.

Bibliografia

• Arkell J, Jackson JC (2003) Constitutive secretion of MMP-9 by early-passage cultured human endothelial cells. Cell Biochem Funct 21: 381-386. 
• Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A (2002) Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 90: 784-791. 
• Ben-Yosef Y, Miller A, Shapiro S, Lahat N (2005) Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. Am J Physiol Cell Physiol 289: C1321-1331. 
• Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH (2003) A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase-2 (MMP-2) transcription by cardiac cells through intreactions wih JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369: 485-496. 
• Birkedal-Hansen H, Taylor RE (1982) Detergent activation of latent collagenase and resolution of its component molecules. Biochem Biophys Res Commun 107: 1173-1178. 
• Cao Y, Fu ZD, Wang F, Liu HY, Han R (2005) Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod Res 7: 205-213. 
• Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395. 
• Catalyurek H, Oktay G, Guzeloglu M, Cavdar Z, Acikel U, Silistreli E, Hazan E (2008) Insulin-blood cardioplegia decreases matrix metalloproteinase activity in ischemia-reperfusion injury during coronary artery bypass surgery. J Int Med Res 36: 551-558. 
• Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG (1996) MMP-2: Expression, activation and inhibition. Enzyme Protein 49: 7-19.  
• Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490. 
• Dhar-Mascareno M, Carcoma JM, Golde DW (2005) Hypoxia-reoxygenation-induced mitochondrial damage and apoptosis in human endothelial cells are inhibited by vitamin C. Free Radic Biol Med 38: 1311-1322. 
• Faller DV (1999) Endothelial cell response to hypoxic stres. Clin Exp Pharmacol Physiol 26: 74-84.  
• Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267: 10931-10934. 
• Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626. 
• Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH (2001) Matrix metalloproteinase inhibition prevents oxidative stres associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21: 1393-1400. 
• Glyn MC, Ward BJ (2002) Changes in the actin cytoskeleton of cardiac capillary endothelial cells during ischemia and reperfusion: the effect of phalloidin on cell shape. J Vasc Res 39: 72-82. 
• Graven KK, Farber HW (1998) Endothelial cell hypoxic stress proteins. J Lab Clin Med 132: 456-453. 
• Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh HV (1993) Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis alpha, interleukin 1 and phorbol ester. Biochem J 296: 803-809. 
• Hernandez-Barrantes S, Toth M, Bernardo MM, Yurkova M, Gervasi DC, Raz Y, Sang QA, Fridman R (2000) Binding of active (57 kDa) membrane type1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP-2) regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 275: 12080-12089. 
• Jackson CJ, Nguyen M (1997) Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 29: 1167-1177. 
• Kiran MS, Kumar-Sameer VB, Viji RI, Sudhakaran PR (2006) Temporal relationship between MMP production and angiogenic process in HUVECs. Cell Biol Int 30: 704-713. 
• Kleiner DE, Stetler-Stevenson WG (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218: 325-329. 
• Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143. 
• Kunz M, Ibrahim SM (2003) Molecular responses to hypoxia in tumor cells. Mol Cancer 2: 23-36.  
• Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi G, Bachetti T, Schultz R (2005) Ischemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26: 27-35. 
• Lee SR, Lo EH (2004) Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab 24: 720-727. 
• Lu A, Clark JF, Broderick JP, Pyne-Geithman GJ, Wagner KR, Ran R, Khatri P, Tomsick T, Sharp FR (2008) Reperfusion activates metalloproteinases that contribute to neurovascular injury. Exp Neurol 210: 549-559. 
• Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378: 151-160. 
• Nakoman C, Resmi H, Ay O, Acikel U, Atabey N, Güner G (2005) Effects of basic fibroblast factor (bFGF) on MMP-2, TIMP-2 and type-1 collagen levels in human lung carcinoma fibroblasts. Biochimie 87: 343-351. 
• Nguyen M, Arkell J, Jackson CJ (2001) Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 33: 960-970. 
• Nilsson I, Shibuya M, Wennström S (2004) Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299: 476-485. 
• Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazen HE, Bazen NG (2004) Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Mol Vis 10: 341-350. 
• Ridgway PF, Ziprin P, Alkhamesi N, Paraskeva PA, Peck DH, Darzi AW (2005) Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg Res 124: 180-186. 
• Sato H, Kinoshita T, Takino K, Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP-2). FEBS Lett 393: 101-104. 
• Seiki M, Yana I (2003) Roles of pericellular proteolysis by membrane type-I matrix metalloproteinases in cancer invasion and angiogenesis. Cancer Sci 94: 569-574. 
• Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241. 
• Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270: 5331-5338. 
• Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 92: 827-839. 
• Wiechelman KJ, Braun RD, Fitzpatrek JD (1988) Investigation of bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175: 231-237. 
• Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154. 
• Yan L, Moses MA, Huang S, Ingber DE (2000) Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci 113: 3979-3987. 
• Yana J, Weiss SJ (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11: 2387-2401. 
• Yang H, Majno P, Morel P, Toso C, Triponez F, Oberholzer J, Mentha G, Lou J (2002) Prostaglandin E1 protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc Res 64: 94-103. 
• Yang H, Zhang WJ, Wu LQ, Gu F, Ye LY, Li J, Xu SQ, Xu YP, Lou JN (2005) Protection of liver sinusoidal endothelial cells from hypoxia-reoxygenation induced apoptosis by alpha-1 antitrypsin in vitro. Zhonghua Yi Xue Za Zhi 85: 106-110. 
• Zhang X, Sakamoto H, Hata Y, Kubota T, Hisatomi T, Murata T, Ishibashi T, Inomata H (2002) Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res 74: 577-584.